ARTICLE | Clinical News

Guselkumab regulatory update

December 1, 2016 3:12 AM UTC

Johnson & Johnson submitted an MAA to EMA for guselkumab to treat moderate to severe plaque psoriasis in adults. The submission includes data from the Phase III VOYAGE 1, VOYAGE 2 and NAVIGATE trials and the Phase II X-PLORE trial. In November, Janssen submitted a BLA to FDA for the indication (see BioCentury, Nov. 28)...

BCIQ Company Profiles

Johnson & Johnson

MorphoSys AG